{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:46Z","timestamp":1783850206609,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21184MFDS286"],"award-info":[{"award-number":["21184MFDS286"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Post-transplantation cyclophosphamide (PTCy) has paved the way for the increased use of alternative donors, including haploidentical familial donors, with acceptable engraftment and graft-versus-host disease (GVHD) rates. However, pharmacokinetic studies of PTCy in the pediatric population following myeloablative conditioning regimens are scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a prospective and comprehensive pharmacokinetic analysis of pre- and post-transplantation cyclophosphamide levels in pediatric patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) using a myeloablative busulfan-based conditioning regimen. A total of 14 samples were collected from each patient. Plasma concentrations of cyclophosphamide and carboxycyclophosphamide were analyzed, and clinical outcomes were recorded. The simulated pharmacokinetic profiles of cyclophosphamide and its metabolites were compared among different age groups using real-world data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 15 pediatric patients (median age at HSCT 9.6 years, range 1.6\u201316.8) were enrolled. Thirteen patients had malignant disease. All patients achieved successful neutrophil engraftment, and the cumulative incidences of grade 2\u20134 acute GVHD and moderate-to-severe chronic GVHD were 13.3% and 14.7%, respectively. The patterns of cyclophosphamide pharmacokinetic parameters were similar between the pre- and post-HSCT doses. The metabolic ratio increased with subsequent doses of PTCy. Patients with severe veno-occlusive disease showed a higher cumulative area under the curve (AUC) of carboxycyclophosphamide (62.6 vs. 40.2\u00a0mg x h\/L, <jats:italic>P<\/jats:italic>\u2009=\u20090.025), while patients with &gt;\u2009grade 3 hemorrhagic cystitis had a higher cumulative AUC of cyclophosphamide (1256.2 vs. 778.2\u00a0mg x h\/L, <jats:italic>P<\/jats:italic>\u2009=\u20090.009). In contrast, there were no notable differences in the pharmacokinetic parameters of cyclophosphamide and carboxycyclophosphamide between the groups with and without acute and chronic GVHD. The AUC of cyclophosphamide and its metabolite were similar in children weighing\u2009\u2265\u200930\u00a0kg and the virtual adult population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study provides insights into the pharmacokinetic profile of cyclophosphamide and its metabolite, carboxycyclophosphamide, in pediatric patients undergoing haploidentical HSCT with PTCy. The intricate interplay between pharmacokinetic parameters and post-HSCT complications suggests the need for tailored adjustments in PTCy dosage, particularly in pediatric patients subjected to myeloablative conditioning regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40364-025-00749-3","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T22:36:06Z","timestamp":1742855766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"13","author":[{"given":"Kyung Taek","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyeun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"1","key":"749_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"749_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14(6):641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"749_CR3","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","volume":"25","author":"LJ Arcuri","year":"2019","unstructured":"Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF. Haploidentical transplantation with Post-Transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: A systematic review and Meta-Analysis. Biol Blood Marrow Transpl. 2019;25(12):2422\u201330.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"25","key":"749_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host disease prophylaxis. N Engl J Med. 2023;388(25):2338\u201348.","journal-title":"N Engl J Med"},{"key":"749_CR5","doi-asserted-by":"crossref","unstructured":"Srinivasan A, Raffa E, Wall DA, Schechter T, Ali M, Chopra Y, Kung R, Chiang KY, Krueger J. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis. Transplant Cell Ther 2022, 28(3):158 e151-158 e159.","DOI":"10.1016\/j.jtct.2021.11.009"},{"issue":"3","key":"749_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41409-020-01063-2","volume":"56","author":"F Saglio","year":"2021","unstructured":"Saglio F, Berger M, Spadea M, Pessolano R, Carraro F, Barone M, Quarello P, Vassallo E, Fagioli F. Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia. Bone Marrow Transpl. 2021;56(3):586\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"749_CR7","doi-asserted-by":"crossref","unstructured":"Hong KT, Park HJ, Kim BK, An HY, Choi JY, Kang HJ. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia. Transplant Cell Ther 2022, 28(4):195 e191-195 e197.","DOI":"10.1016\/j.jtct.2022.01.002"},{"issue":"10","key":"749_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","volume":"31","author":"A Bashey","year":"2013","unstructured":"Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, Solomon SR. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(10):1310\u20136.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"18","key":"749_CR9","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1182\/bloodadvances.2023010281","volume":"7","author":"JC Fierro-Pineda","year":"2023","unstructured":"Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, Davis J, Egeler M, Huo J, Hudspeth M, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7(18):5639\u201348.","journal-title":"Blood Adv"},{"issue":"7","key":"749_CR10","first-page":"2122","volume":"109","author":"A Ruggeri","year":"2024","unstructured":"Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, Czyzewski K, Skorobogatova E, Sedlacek P, Besley C, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109(7):2122\u201330.","journal-title":"Haematologica"},{"issue":"16","key":"749_CR11","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","volume":"4","author":"HJ Symons","year":"2020","unstructured":"Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, Klein O, Llosa N, Zambidis ET, Ambinder R, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4(16):3913\u201325.","journal-title":"Blood Adv"},{"issue":"11","key":"749_CR12","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.bbmt.2018.06.034","volume":"24","author":"KT Hong","year":"2018","unstructured":"Hong KT, Kang HJ, Choi JY, Hong CR, Cheon JE, Park JD, Park KD, Song SH, Yu KS, Jang IJ, et al. Favorable outcome of Post-Transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted Busulfan-Based myeloablative conditioning using intensive Pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transpl. 2018;24(11):2239\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"749_CR13","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1080\/10428194.2022.2087067","volume":"63","author":"KS Kasudhan","year":"2022","unstructured":"Kasudhan KS, Patil AN, Jandial A, Khadwal A, Prakash G, Jain A, Bhurani D, Ahmed R, Agrawal N, Singh R, et al. Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. Leuk Lymphoma. 2022;63(11):2679\u201385.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"749_CR14","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-05-2079","volume":"12","author":"DH Salinger","year":"2006","unstructured":"Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, McDonald GB, Vicini P. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a bayesian Pharmacokinetic approach. Clin Cancer Res. 2006;12(16):4888\u201398.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"749_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","volume":"41","author":"SM Yule","year":"1996","unstructured":"Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol. 1996;41(1):13\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"749_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/petr.12724","volume":"20","author":"SR Jaiswal","year":"2016","unstructured":"Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: the need to look beyond post-transplantation cyclophosphamide in younger children. Pediatr Transpl. 2016;20(5):675\u201382.","journal-title":"Pediatr Transpl"},{"issue":"1","key":"749_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbmt.2014.09.013","volume":"21","author":"JW Lee","year":"2015","unstructured":"Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim NH, Jang MK, Kim H, Song SH, Park JD, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transpl. 2015;21(1):190\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"749_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, et al. National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389\u2013e401381.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"749_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, et al. International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"749_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2018;53(2):138\u201345.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"749_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.clpt.2004.05.006","volume":"76","author":"R Qiu","year":"2004","unstructured":"Qiu R, Yao A, Vicini P, McDonald GB, Batchelder AL, Bouvier ME, Cole SL, Slattery JT. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Clin Pharmacol Ther. 2004;76(3):270\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"749_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","volume":"58","author":"R Dul\u00e9ry","year":"2023","unstructured":"Dul\u00e9ry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, Maisano V, Chabannon C, Malard F, Brissot E, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transpl. 2023;58(4):386\u201392.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"749_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","volume":"58","author":"R Dul\u00e9ry","year":"2023","unstructured":"Dul\u00e9ry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, Calabro M, Van de Wyngaert Z, Bonnin A, Ledraa T, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte Globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transpl. 2023;58(11):1215\u201322.","journal-title":"Bone Marrow Transpl"},{"key":"749_CR24","doi-asserted-by":"crossref","unstructured":"Olivares-Gazca JC, Pastel\u00edn-Mart\u00ednez ML, Montes-Robles MA, Gallardo-P\u00e9rez MM, Hern\u00e1ndez-Flores EJ, Robles-Nasta M, S\u00e1nchez-Bonilla D, Ruiz-Delgado GJ. Ruiz-Arg\u00fcelles GJ: Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? Hematology 2023, 28(1):2242176.","DOI":"10.1080\/16078454.2023.2242176"},{"issue":"5","key":"749_CR25","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00277-023-05300-8","volume":"103","author":"LJ Arcuri","year":"2024","unstructured":"Arcuri LJ, Ribeiro AAF, Hamerschlak N, Kerbauy MN. Posttransplant cyclophosphamide beyond haploidentical transplantation. Ann Hematol. 2024;103(5):1483\u201391.","journal-title":"Ann Hematol"},{"issue":"10","key":"749_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.ejca.2011.03.008","volume":"47","author":"G Chinnaswamy","year":"2011","unstructured":"Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Eur J Cancer. 2011;47(10):1556\u201363.","journal-title":"Eur J Cancer"},{"issue":"1","key":"749_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0091270008325928","volume":"49","author":"JS McCune","year":"2009","unstructured":"McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the children\u2019s oncology group. J Clin Pharmacol. 2009;49(1):88\u2013102.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"749_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1046\/j.1365-2125.1999.00090.x","volume":"48","author":"M Hassan","year":"1999","unstructured":"Hassan M, Svensson US, Ljungman P, Bj\u00f6rkstrand B, Olsson H, Bielenstein M, Abdel-Rehim M, Nilsson C, Johansson M, Karlsson MO. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol. 1999;48(5):669\u201377.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"749_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00228-013-1507-7","volume":"69","author":"IW Kim","year":"2013","unstructured":"Kim IW, Yun HY, Choi B, Han N, Kim MG, Park S, Oh JM. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol. 2013;69(8):1543\u201351.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"749_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0009-9236(98)90178-3","volume":"64","author":"S Ren","year":"1998","unstructured":"Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther. 1998;64(3):289\u2013301.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"749_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","volume":"13","author":"JS McCune","year":"2007","unstructured":"McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB. Cyclophosphamide following targeted oral Busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transpl. 2007;13(7):853\u201362.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"749_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","volume":"19","author":"AR Rezvani","year":"2013","unstructured":"Rezvani AR, McCune JS, Storer BE, Batchelder A, Kida A, Deeg HJ, McDonald GB. Cyclophosphamide followed by intravenous targeted Busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transpl. 2013;19(7):1033\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"749_CR33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","volume":"101","author":"GB McDonald","year":"2003","unstructured":"McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043\u20138.","journal-title":"Blood"},{"issue":"9","key":"749_CR34","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","volume":"94","author":"ME de Jonge","year":"2006","unstructured":"de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer. 2006;94(9):1226\u201330.","journal-title":"Br J Cancer"},{"issue":"Supplement 1","key":"749_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2021-146997","volume":"138","author":"MJ McAdams","year":"2021","unstructured":"McAdams MJ, Hyder M, Dimitrova D, Sadler JL, McKeown C, Steinberg SM, Chai A, Napier S, Stokes A, Sponaugle J, et al. Phase I\/II study of reduced dosing of Post-Transplantation cyclophosphamide (PTCy) after HLA-Haploidentical bone marrow transplantation. Blood. 2021;138(Supplement 1):101\u2013101.","journal-title":"Blood"},{"issue":"3","key":"749_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","volume":"56","author":"J Sugita","year":"2021","unstructured":"Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T, Miyazaki Y, Kumagai H, Matsuo K, Akashi K, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transpl. 2021;56(3):596\u2013604.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"749_CR37","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.bbmt.2019.07.010","volume":"25","author":"M Ayas","year":"2019","unstructured":"Ayas M, Siddiqui K, Al-Jefri A, Al-Ahmari A, Ghemlas I, Al-Saedi H, Alanazi A, Jafri R, Ayas MF, Al-Seraihi A. Successful outcome in patients with Fanconi Anemia undergoing T cell-Replete mismatched related donor hematopoietic cell transplantation using Reduced-Dose cyclophosphamide Post-Transplantation. Biol Blood Marrow Transpl. 2019;25(11):2217\u201321.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"749_CR38","first-page":"695","volume":"103","author":"CIS Barker","year":"2018","unstructured":"Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, de Wildt SN, Offringa M. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child. 2018;103(7):695\u2013702.","journal-title":"Arch Dis Child"},{"issue":"6","key":"749_CR39","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/pr.2018.38","volume":"83","author":"LE Kelly","year":"2018","unstructured":"Kelly LE, Sinha Y, Barker CIS, Standing JF, Offringa M. Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. Pediatr Res. 2018;83(6):1095\u2013103.","journal-title":"Pediatr Res"},{"issue":"9823","key":"749_CR40","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric Haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (London England). 2012;379(9823):1301\u20139.","journal-title":"Lancet (London England)"},{"issue":"8","key":"749_CR41","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41409-023-02007-2","volume":"58","author":"S Corbacioglu","year":"2023","unstructured":"Corbacioglu S, Grupp SA, Richardson PG, Duarte R, Pagliuca A, Ruutu T, Mahadeo K, Carreras E. Prevention of veno-occlusive disease\/sinusoidal obstruction syndrome: a never-ending story and no easy answer. Bone Marrow Transplant. 2023;58(8):839\u201341.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"749_CR42","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, D\u00edaz-Bey\u00e1 M, Rosi\u00f1ol L, Mart\u00ednez C, Fern\u00e1ndez-Avil\u00e9s F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2011;17(11):1713\u201320.","journal-title":"Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"issue":"2","key":"749_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2010;16(2):157\u201368.","journal-title":"Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"issue":"11","key":"749_CR44","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41409-020-0918-1","volume":"55","author":"Z Szmit","year":"2020","unstructured":"Szmit Z, Gorczynska E, Kr\u00f3l A, Ussowicz M, Mielcarek-Siedziuk M, Olejnik I, Panasiuk A, Ka\u0142wak K. Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? Prospective evaluation of pediatric EBMT criteria for VOD. Bone Marrow Transplant. 2020;55(11):2138\u201346.","journal-title":"Bone Marrow Transplant"}],"updated-by":[{"DOI":"10.1186\/s40364-025-00781-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000}}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00749-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:02:52Z","timestamp":1745823772000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00749-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40364-025-00781-3","URL":"https:\/\/doi.org\/10.1186\/s40364-025-00781-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Seoul National University Hospital and written informed consent was obtained from the legal guardians of all participating patients before any study procedures commenced.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}